Brought to you by 
Medimetriks gets commercial rights to Grupo Ferrer's ozenoxacin
08 Mar 2018
Executive Summary
Grupo Ferrer Internacional SA granted Medimetriks Pharmaceuticals Inc. rights to commercialize its ozenoxacin 1% cream in the US, Puerto Rico, and US Virgin Islands.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com